phasizes the induration of bile ducts which results from chronic inflammation and fibrosis. The term cholangitis indicates inflammation of the bile duct. This term is often used not only to describe the pathologic abnormalities but also in a clinical sense to describe episodes of jaundice, abdominal pain, and fever. However, the literal meaning of cholangitis is more relevant, because the occurrence of clinical cholangitis is uncommon in unoperated patients with PSC.
The diagnosis of PSC is based on: (i) selection criteria, these being clinical, biochemical, radiologic and histologic; and (ii) exclusion criteria. In an appropriate clinical setting (e.g., a male with chronic ulcerative colitis), a twofold or greater elevation of the serum biliary enzyme levels (e.g., alkaline phosphatase and 7-glutamic transpeptidase) is typical. 1,2 Recently, serologic markers have been described (i.e., neutrophil cytoplasmic antibodies and neutrophil nuclear antibodies) in the serum of most patients with PSC. 5 '6 Radiologic criteria include the presence of multifocal, diffusely distributed strictures of the biliary system. 4 These strictures are often associated with tortuosity and irregularity of the extrahepatic and intrahepatic bile duct (Fig. 1) .
Hepatic histologic abnormalities seen in PSC can be categorized in the following fashion: cholangitis or portal hepatitis (stage I); periportal hepatitis or periportal fibrosis (stage II); septal fibrosis extending beyond the limiting plate (stage III); and biliary cirrhosis (stage IV). 7'8 Finally, a patient with prior bile duct surgery (other than simple cholecystectomy) or documented choledocholithiasis prior to symptoms may have the secondary rather than the primary variety of sclerosing cholangitis.
In most cases, an abnormal cholangiogram is required for the diagnosis PSC. Most authorities would consider the diagnosis if either intrahepatic or extrahepatic ducts were involved. Furthermore, a small duct variety of PSC with no abnormalities on cholangio- frequency of diagnosis of PSC is likely due both to an increase in clinical awareness and to increased utilization of certain diagnostic methods, such as endoscopic retrograde cholangiography (ERC). m, ll
There are no firm data on the prevalence of PSC, so crude estimates are necessary. In the United States, the prevalence of chronic ulcerative cholitis (CUC) is reported to be 40-100 cases per 100000 population. Since approximately 4% of CUC patients may have PSC (Table 3) , one can estimate the prevalence of PSC to be 1-4 cases per 100000 population. This approach likely underestimates the true frequency of PSC, since not all patients with PSC have CUC.
According to a statistical report of the Japanese ministry of Health and Welfare in 1990, the prevalence of ulcerative colitis was 7.14 per 100 000 population. 12 These data suggest that the number of PSC cases in Japan is small compared to that in the United States. Moreover, the reported number of cases of PSC associated with CUC is considerably lower in Japan than in the United States. 12 PSC is predominantly a disease of young men; approximately 70% of patients are male and, at the time of diagnosis, the average age is 40 years. 2 graphy but an abnormal liver biopsy has also been described (Table 2) . s
Clinical features
Before 1980, PSC had been reported in no more than 100 cases. 9 However, this situation has dramatically changed and now PSC is one of the two most common adult chronic cholestatic diseases, the other being primary biliary cirrhosis (PBC). Moreover, in the United States, PSC is one of the most common indications for liver transplantation in adults. This increase in the LFT, liver function tests Patients with PSC present clinically in a variety of different ways (Table 4) . With or without associated CUC, most patients with PSC show a cholestatic biochemical profile on laboratory testing, even in the absence of symptoms. Alternatively, patients may present with pruritus and fatigue. Patients with PSC may also present with episodes of fever and abdominal pain with or without associated jaundice. Such episodes of recurrent cholangitis occur more commonly in PSC patients who have undergone previous biliary tract surgery such as choledochoenterostomy. Occasionally, the first symptoms of PSC may be due to complications of advanced disease, such as ascites or bleeding from gastroesophageal varices. Occasionally, the diagnosis is made at laparotomy for undetermined jaundice. In such cases, the diagnosis of PSC will be suspected because of the rope-like nature of the common bile duct on palpitation; an operative cholangiogram will then show changes characterstic of PSC.
For the sake of completeness, several uncommon modes of presentation of PSC should be mentioned, including: (i) patients with recurrent fever and septicemia of unknown etiology; (ii) patients with a remote proctocolectomy and ileostomy for CUC who present with peristomal variceal bleeding (see below); (iii) patients with steatorrhea and weight loss due to either complicating pancreatic exocrine insufficiency or associated nontropical sprue; and (iv) patients with inflammatory bowel disease and a previous diagnosis of idiopathic or autoimmune chronic active hepatitis that does not respond to standard immunosuppressive therapy. 13 PSC usually begins insidiously, making it difficult to determine the exact time the illness began. Nonetheless, most patients with symptoms have had them for an average of 12-24 months before diagnosis. The gradual onset of progressive fatigue and pruritus followed by jaundice represents the most frequent symptom complex that leads to the diagnosis of PSC.
In our experience, almost three-fourths of patients with PSC will have some abnormality on physical examination at the time of diagnosis ( Table 5 ). The most common features are hepatomegaly, icterus, and/or splenomegaly. 1"11'14-17 It is notable that findings such as hyperpigmentation, xanthelasthma, and xanthomas occur less often than in PBC, a syndrome with which PSC shares many features. 2"3"18 A variety of diseases have been seen in association with PSC. Inflammatory bowel disease is the most common and most important disease associated with PSC: the frequency of this association is shown in Table 6 . The average frequency with which inflammatory bowel disease is associated with PSC in western countries is 77%,2'3'19'2~ whereas in Japan, the number is reported to be only 18%. 21 Obviously, the frequency varies depending on the type of screening tests used to examine for the presence of inflammatory bowel disease. These data show that the most common form of inflammatory bowel disease associated with PSC is CUC; Crohn's colitis and Crohn's ileocolitis are associated much less often. Moreover, the ulcerative colitis which occurs in association with PSC most commonly involves a major portion of the colon, frequently shows rectal sparing, and is more likely to be found in male than in female patients. Additional features of the association include the following: (i) there are no apparent differences between patients with PSC alone and PSC associated with inflammatory bowel disease with respect to hepatobiliary symptoms and signs, biochemical tests, cholangiograms, and liver histology; (ii) although the diagnosis of inflammatory bowel disease usually precedes the diagnosis of PSC, the diagnosis of PSC may precede that of inflammatory bowel disease; (iii) the inflammatory bowel disease associated with PSC is usually symptomatically quiescent or mild; however, some patients with PSC and CUC require colectomy for bowel symptoms. 22 The other diseases seen in association with PSC, such as sarcoidosis, occur much less often and are much less important clinically.
As shown in Table 7 , we can conveniently categorize the complications of PSC under two major headings: general complications (i.e., those common to any form of chronic liver disease), and specific complicatiolls (i.e., those that appear to be peculiar to PSC). Liver failure and portal hypertension occur in PSC, as they do in any other form of chronic liver disease. Hepatic osteodystrophy, which refers to the metabolic bone disease associated with chronic cholestatic liver disease, and the malabsorption of fat-soluble vitamins resulting most often from intraluminal bile acid deficiency, occur often in PSC as a result of chronic cholestasis. All these complications should be managed In contrast, those complications that are specific to PSC provide unique and difficult management problems. Although PSC most commonly involves the whole biliary system, the lesions are not equally distributed; thus, a dominant stricture (i.e., areas of localized high-grade narrowing) may occur and may cause rapid worsening of jaundice and recurrent episodes of cholangitis. Moreover, it is very difficult to distinguish these benign narrow strictures from highgrade strictures secondary to complicating adenocarcinoma of the bile duct (see below). Cholelithiasis appears to occur more commonly in patients with PSC; in our experience, about 25% of patients with PSC will have gallstones. 17 Also, choledocholithiasis may complicate PSC.
Currently, adenocarcinoma of the bile duct represents the most lethal complication of PSC. 1-3"17 '23 Although the frequency with which this malignancy complicates PSC is not exactly clear, a figure Of about 10% is likely. Risk factors for the development of cholangiocarcinoma in the setting of PSC include age, cirrhosis, portal hypertension, and long-standing CUC. 23"24 However, this complication may occur even in young patients without advanced liver disease or CUC. The outcome of this malignancy in patients with PSC, regardless of the form of therapies employed, is virtually always death, with an overall median survival of about 5 months after diagnosis. Finally, patients with PSC who have undergone proctocolectomy for associated CUC with ileostomy frequent develop varices around the ostomy stoma as a manifestation of portal hypertension. 25 These varices are painful, bleed often, and frequently require transfusions, and can be reversed only by reducing the portal hypertension, ideally by performing orthotopic liver transplantation (OLT).
Biochemical tests
As shown in Table 8 , patients with PSC have multiple biochemical abnormalities at the time of diagnosis. Commonly, patients with PSC will have an elevated serum alkaline phosphatase level, usually greater than five times the upper normal limit. 2'3 Only in very rare cases is the serum alkaline phosphatase normal. 26 Similarly, most patients will have mild increases of their serum alanine or aspartate aminotransferase levels. At the time of diagnosis, one-half to two-thirds of patients with PSC will have an increase in their total serum bilirubin. Is Bilirubin levels fluctuate considerably, with high levels suggesting disease progression or the development of complications such as a benign dominant stricture or superimposed adenocarcinoma of the bile duct. 2'1~ Serum albumin levels and prothrombin time are commonly normal at the time of diagnosis; these tests will show abnormalities with disease progression. 2 It is noteworthy that tests related to copper metabolism are virtually always abnormal in patients with PSC. 27 Serum copper and serum ceruloplasmin levels are commonly increased, and urine copper excretion is accelerated. Moreover, hepatic tissue copper levels are increased in most patients with PSC, frequently in the range seen in Wilson's disease and PBC. The abnormalities in copper metabolism reflect the cholestatic nature of the syndrome.
Until recently, there were no Serologic markers specific for PSC. For instance, tests for anti-mitochondrial antibody are usually (>90%) negative. 2'3'1~ '19 Similarly, anti-smooth muscle antibodies are most often negative. Although serum IgM levels may be increased in PSC, they rarely reach the levels seen in PBC. 3 Recently, antibodies to as yet unidentified antigens present in the cytoplasm and the nucleus of neutrophils have been described in approximately 70% of patients with PSC. 6 Finally, eosinophilia of a mild to moderate degree may rarely be seen in PSC.
Radiologic features
The development of endoscopic and transhepatic cholangiographic techniques has been the major reason for the increased frequency of diagnosis of PSC. In most cases, the cholangiogram will show characteristic features in PSC. 4 The radiologic features most commonly seen in the syndrome include: (i) diffusely disturbed, multifocal annular strictures with intervening segments of normal or slightly ectatic ducts (Fig.  1) ; (ii) short band-like strictures (Fig. 2) ; and (iii) diverticulum-like outpouchings (Fig. 3) .
In perhaps 15% of patients with PSC, the pancreatic duct may also be abnormal. The diffuse narrowing of the main pancreatic duct with multiple short strictures and ectatic intervening segments resembles the abnormalities seen in chronic pancreatitis. Cholangiographic abnormalities of the gallbladder and cystic duct may also be seen occasionally in patients with PSC.
Hepatic histology
Virtually all patients with PSC will show histologic abnormalities on liver biopsy. 7's The main features on biopsy specimens include periductal fibrosis and in- Many patients with PSC will have fibrous-obliterative cholangitis (chronic nonsuppurative obliterative cholangitis) on biopsy. When seen, this lesion is near diagnostic for PSC (Fig. 4) .
From a histologic viewpoint, abnormalities seen on liver biopsy from PSC patients must be distinguished from those seen in PBC, prolonged extrahepatic obstruction, and chronic active hepatitis. Indeed, PBC has many histologic features on liver biopsy specimens that overlap with those seen in PSC, including periportal cholestasis, copper deposition, and granulomas. Nonetheless, the classic "florid duct" lesion is not seen in PSC and is essentially pathognomonic of PBC. Conversely, fibrous obliterative cholangitis, which is the histologic hallmark of PSC, has not been seen in PBC.
Etiopathogenesis
The etiopathology of PSC is still unknown: (i) genetic, (ii) acquired, and (iii) immunological factors are thought to play a significant role in the development of this entity (Table 9 ). Until recently, there have been no promising animal models of PSC that may have given any insights into the pathogenesis of the disease; however, the development of animal models of cholangitis have been reported from several laboratories, including ours. as-3~
Several studies show results consistent with a major role for genetic factors in the etiopathogenesis of PSC. Familial occurrence of PSC has been reported. 31 '32 Y. Ueno and N.F. LaRusso: Primary sclerosing cholangitis 46 While cytomegalovirus (CMV) may affect intrahepatic bile ducts and cause histological changes, the morphological changes generally differ from those seen in PSC. 47 Reovirus type Ill has been associated with neonatal biliary atresia which, like PSC, is characterized by obliterative cholangitis. 46'4a-5~ However, no direct evidence links Reovirus infections to the development of PSC. Nevertheless, other viruses may be involved in the pathogenesis of PSC. The availability of polymerase chain reaction (PCR) technology, which is now a standard approach to detect viral genes, will enable investigators to examine for viral gene products in the serum and liver of patients with PSC. We have used this approach to demonstrate that CMV gene products are absent from the livers of patients with PSC. 47 Currently, several studies have shown that abnormalities of the immune system are associated with PSC. For example, PSC is often associated with CUC and, to a lesser extent, with nontropical sprue, two diseases thought to result from alterations in the immune system. Moreover, linkage to certain HLA haplotypes, especially HLA-B8, 33 the presence of circulating immune complexes, 51 decreased clearance of immune complexes, 52 and increased complement metabolism 53 support an immunological basis for PSC. In addition, cells involved in the destruction of bile ducts in PSC have been shown recently to be T lymphocytes, especially CD8-positive (suppressor/cytotoxic) T lymphocytes, and abnormalities in peripheral blood lymphocyte subsets have also been demonstrated. 54 56 Also, enhanced autoreactivity of suppressor/cytotoxic T-lymphocytes from the peripheral blood of patients with PSC has been reported, s4 Recent findings indicate that MHC class II antigens, which are normally expressed only by immune lineage ceils, are aberrantly expressed on bile duct cells in PSC. 57 59 This phenomenon is also observed in other cholangiophathies, such as PBC and allograft rejection, s7 More interestingly, colonic epithelia are also reported to aberrantly express MHC class II antigen in CUC. 6~ These studies support abnormalities in the immune system as being pathogenetically related to the development or perpetuation of PSC. However, the current lack of suitable immune animal models of PSC makes it difficult to develop further insight into this disease. Recently, we reported immune-mediated cholangitis developing in rats after active immunization with rodent bile duct cells. 3~ The cholangitis observed in this model has features similar to human cholangiopathies (e.g., T lymphocyte-predominant infiltration). Moreover, we also found that bile duct cells expressed MHC II antigens and functioned as antigen-presenting cells in this rat model. 6~ These findings imply that bile duct cells may play a central role in expressing target antigens that are recognized by auto-reactive T lymphocytes.
Differential diagnosis
If the clinician is aware of the syndrome, the diagnosis of PSC is usually not difficult. For example, PSC should be the first diagnosis to be considered in a male with chronic cholestatic liver test abnormalities and inflammatory bowel disease. In such patients, the first major diagnostic study should be a cholangiogram. In most cases, an endoscopic rather than transhepatic approach is preferable because: (i) the endoscopic approach is less uncomfortable in most patients; (ii) the rate of successful visualization of bile ducts endoscopically in patients with PSC is probably higher; (iii) if necessary, one can visualize the pancreatic duct as well. A transhepatic approach is certainly acceptable, particularly in patients with previous biliary tract reconstructive surgery in whom the endoscopic route may be difficult or impossible. A liver biopsy is also useful for providing diagnostic confirmation, since a small percentage of patients with PSC (i.e., those with small duct PSC) have normal cholangiograms and show typical features only on liver biopsy. However, the major value of liver biopsy is for histologic staging and for estimating prognosis.
The other syndromes that must be considered in the differential diagnosis of PSC are listed in Table 10 . Secondary sclerosing cholangitis is relatively easily excluded by efforts to identify specific causative agents. In a woman with chronic cholestasis, especially if she is middle-aged, PBC would be the leading diagnosis. The most useful diagnostic test in distinguishing PSC from PBC is a cholangiogram. The extrahepatic bile ducts should not be involved in PBC and eventually 
Natural history
Until recently, the natural history of PSC was obscure, primarily because of our lack of knowledge of its pathogenesis, the unavailability of serologic markers for diagnosis, and the unpredictable nature of the syndrome. Nevertheless, based on a variety of recent studies, most would agree that PSC is a progressive syndrome leading to significant complications related to chronic cholestasis, and eventually to liver failure. The largest of several recent studies addressing this issue analyzed data on nearly 200 patients with PSC.13'63'64 During this study, 31% died as a result of underlying liver disease or the development of cholangiocarcinoma; an additional 10% were referred for OLT. 13 Median survival from the time of diagnosis was 12 years, and both symptomatic and asymptomatic patients had reduced survival when compared to age, sex, and race-matched United States populations. This and other studies strongly suggest that PSC is a progressive disease that will lead to death from liver failure unless liver transplantation is performed or effective medical therapy becomes available. Studies also show that asymptomatic patients often have a progressive disease course. 65 To predict survival based on the clinical, biochemical, and histologic features of PSC is important for the timing of liver transplantation. Attempts to evaluate prognosis have employed univariant and multivariant approaches. 11,13,14,64 An association between increased hepatic and urinary copper levels and diminished survival represents an example of the univariant approach. The multivariant approach, while requiring more sophisticated statistics, most notably the Cox multivariant regression analysis, is more appropriate in a disease with a fluctuating course such as PSC. The first report using the Cox regression analysis is attributed to Helzberg et al., 14 who showed that the presence of hepatomegaly and a serum bilirubin of >l.5mg/dl were independent predictors of poor prognosis in patients with PSC. The most recent mathematical model to predict survival in PSC patients utilized a geographically heterogeneous patient population from five major medical centersJ '6 This study found that age, serum bilirubin, hepatic histologic stage, and the presence or absence of splenomegaly were independent predictors of survival.
Management

General issues
Since no specific and effective medical therapy is available for PSC, the first decision for the physician is whether or not any therapeutic intervention is required. Especially in the asymptomatic patient with minimal liver test dysfunction and early histologic lesions by liver biopsy, observation may be a reasonable approach. Alternatively, experimental therapy, particularly if it is safe, might be considered in the context of a randomized controlled trial. This kind of approach may be modified in the future, with additional progress in our understanding of the natural history of PSC. The specific goals of treatment, such as the relief of symptoms, the correction of complications, or therapy of the underlying liver disease, should be clarified. For example, pruritus and fat-soluble vitamin deficiencies are common problems in patients with cholestatic liver disease; conventional approaches to their management, which will not be mentioned here, are reasonable. 67 Similarly, if complications such as rupture of esophageal varices develop, standard interventions (e.g., variceal sclerosis) should be considered as well. Assuming the decision is made to intervene, then three therapeutic approaches are available for the treatment of patients with PSC (Table 11 ). These approaches include: (i) medical treatment; (ii) therapy of complications; and (iii) surgical treatment.
Medical treatment of the underlying liver disease
Medical approaches for the underlying liver disease in PSC have focused principally on the use of cupruretic, antifibrogenic, immunosuppressive, and choleretic agents (Table 11) .
Up to now, only a limited number of controlled trials of any form of medical therapy in PSC have been carried out. Unfortunately, no drugs have been proven effective in the treatment of this condition.
The finding of elevated hepatic copper levels in PSC prompted the initiation of a therapeutic trial of Dpenicillamine. A randomized, double-blind controlled trial comparing D-penicillamine with placebo was reported by us in 1988. 37 The trial involved 70 patients, 39 randomized to the drug and 31 to the placebo. The trial was initiated in 1980 and patients were followed until 1986. The median follow-up time was 4.6 years. Penicillamine showed no advantage over placebo with respect to clinical features, biochemistry, histology, or patient survival.
We recently reported our initial experience with combined prednisone and colchicine in 12 patients with PSC compared to 12 untreated patients matched for age, se x , initial biochemical abnormalities, and liver histology. 6s While we observed improvement in several biochemical parameters (i.e., bilirubin, alkaline phosphatase, and aspartate aminotransferase) at 6 and 12 months after entry, the differences were not sustained at 2 years. Although the study group was small, it led us to conclude that this drug combination was not a promising option for the treatment of PSC.
A variety of agents that are known or suspected to affect the immune system have been evaluated in uncontrolled trials in PSC. Corticosteroids have been used, both topically and systematically, in several small studies. 69'7~ A small controlled trial of nasobiliary lavage with corticosteroid versus placebo revealed no difference between drug and placebo. Uncontrolled observations in a small number of patients with a marked inflammatory component to their PSC showed impressive responses to orally administered corticosteroids; other uncontrolled studies have shown no benefit. Azathioprine has been used in individual patients, without apparent benefit. 71'72 Cyclosporine, a new immunosuppressive agent which inhibits the production of interleukin 2 by T lymphocytes, resulting in decreased T lymphocyte activation and proliferation, was evaluated at our institution; results showed no beneficial effect on symptoms, biochemical live tests, or disease-free survivai. 73 Recent uncontrolled studies with methotrexate have shown promise in PSC; results include improvement in biochemical tests, apparent stabilization in bile duct scarring, and possible improvement in liver histology. 74 Findings of controlled trials are anxiously awaited, although the initial results are not promising. Several other agents known to affect the immune system (e.g., FK506) are potential treatment approaches in PSC, but they have yet to be evaluated.
Considerable recent interest has focused on the use of ursodeoxycholic acid, the 7-13 epimer of chenodeoxycholic acid, in the treatment of PSC. 75"7(' This agent has been shown to be of benefit in the management of patients with PBC; its efficacy is presumed to be due to its cytoprotective and choleretic effects; it may also reduce aberrant HLA antigen expression on bile duct cells, impair T cell response, and replace more hydrophobic, endogenous toxic bile acids that accumulate in cholestasis. 7s Two small controlled trials with this agent have shown improvement in biochemical tests without an effect on liver histology and time to transplantation .77,78
Therapy of complications
As we noted earlier (Table 7) , the complications of PSC include those that are relatively specific for this chronic cholestatic syndrome. Therapeutic approaches for these major specific complications are available, although their effectiveness is quite variable.
Patients with recurrent episodes of cholangitis without dominant stricture formation should be treated with broad-spectrum antibiotics. Prophylactic antibiotics for patients with frequent episodes of cholangitis are reasonable; however, their efficacy has not been established by randomized trials. Patients who develop dominant strictures in the biliary tract with increases in serum bilirubin levels, recurrent episodes of cholangitis, or pruritus should be considered for balloon dilatation of these strictures (i.e., cholangioplasty). Depending upon the location of the structures, either an endoscopic or a transhepatic approach is acceptable. Our own experience with transhepatic balloon dilatation has shown that this modality is effective in alleviating pruritus and in diminishing the frequency of cholangitic episodes secondary to dominant strictures. 79'8~ Approximately 10% of patients with PSC with develop superimposed adenocarcinoma of the bile duct. 1-3'13'14 Our recent findings suggest that monitoring serum CA-19-9, a tumor-associated antigen, may be useful for diagnosis of this malignant complication sl. The management of a suspected or established cholangiocarcinoma superimposed on PSC is complicated, is in evolution, and is largely ineffective. If the malignancy is surgically resectable and the patient is not currently a candidate for liver transplantation, an attempt at surgical resection would be seem reasonable; unfortunately, this approach is usually unsuccessful. Alternatively, if the cholangiocarcinoma is not surgically resectable, or if it is resectable but the patient has advanced parenchymal liver disease, consideration should given to orthotopic liver transplantation, recognizing that the outcome of transplantation for cholangiocarcinoma complicating PSC has, to date, been poor. Treatment protocols that supplement liver transplantation with adjuvant chemotherapy and radiation for patients with PSC and cholangiocarcinoma are underway.
Surgical treatment
Three surgical options could theoretically be of value in the treatment of PSC: (i) biliary tract reconstructive procedures; (ii) proctocolectomy in patients with PSC and CUC; and (iii) orthotopic liver transplantation (Table 11) .
We consider a biliary tract reconstructive procedure to be in the same category as balloon dilatation of dominant strictures; namely, it represents a palliative procedure whose objective is to reduce symptoms rather than to affect the natural history of the underlying hepatobiliary disease. 79,8~ This opinion is based on our own experience that there is no particular beneficial effect from this type of surgical procedure on the natural history of the underlying liver disease in PSC.
The frequent association of CUC and PSC has suggested to some that removal of the colon may affect the liver by preventing the passage of toxic or infectious agents through an abnormal mucosa to the liver. However, a retrospective analysis of patients with both PSC and CUC showed no difference in the progression of clinical, biochemical, histologic, or cholangiographic features in patients with or without proctocolectomy. 22 Proctocolectomy may be appropriate in patients with PSC and CUC for traditional colonic indications (e.g., medical intractability, development of persistent highgrade dysplasia, etc.).
Orthotopic liver transplantation (OLT) is a serious consideration for patients with any form of advanced liver disease, including PSC. Indeed, at many major transplant centers in the United States including our own, PSC represents one of the most frequent indications for liver transplantation in adults. Recent results suggest that the outcome of liver transplantation in patients with PSC is not different from the outcome in patients with other forms of noninfectious, nonmalignant chronic liver disease, with 5 year survivals being 75%-85%. s2 However, despite the excellent survival, special problems may occur after liver transplantation in patients with PSC. For instance, diffuse biliary stricturing occurs more frequently in PSC patients who undergo OLT than it does in patients with PBC who undergo this procedure. While biliary stricturing after OLT for PSC raises the question of recurrent disease, other factors (e.g., reflux of intestinal contents with associated chemical or bacterial cholangitis related to the Roux-en-Y biliary anastomosis; ductopenic rejection, which occurs more frequently in PSC patients) represent alternative etiologies for biliary stricturing in PSC after transplantation. Finally, while symptoms related to inflammatory bowel disease generally remain minimal after OLT, colon cancer has been reported following OLT in patients with PSC and associated CUC, emphasizing the importance of continued colon cancer screening in these patients.
Up to now, the concept of brain death seems generally not to be accepted in Japan, and under these circumstances, OLT is not an available option in that country; however, its efficacy in a variety of chronic liver diseases is well established in other countries.
Conclusions
Primary selerosing cholangitis is a progressive, sometimes fatal, hepatobiliary disorder for which no corn-pletely effective medical therapy exists. The syndrome, which is often found in young men, is characterized by a frequent association with chronic ulcerative colitis, chronic cholestasis, hepatic copper overload, and characteristic abnormalities on liver biopsy specimens and in virtually all cholangiograms. Although a definitive conclusion about the natural history of the syndrome requires additional investigations, many findings suggest that the disease progresses slowly and relentlessly over 5-15 years, from an asymptomatic stage to a condition characterized by cholestasis and complicated by cirrhosis, portal hypertension, and, in approximately 10% of patients, adenocarcinoma of the bile ducts. Management should first involve a thoughtful decision to observe, which may be reasonable in some asymptomatic patients with early disease, or to intervene, especially in symptomatic patients, in the context of randomized, controlled clinical trials. However, before medication is undertaken, therapeutic goals need to be defined and should focus on either alleviating symptoms, dealing effectively with complications, or attempting to improve the underlying liver disease. Symptomatic treatment and therapy for complications are similar to those employed in other chronic liver disease. Proctocolectomy in a patient with PSC and CUC is not beneficial in improving the underlying liver disease. In contrast, orthotopic liver transplantation, which is not currently available in Japan, may be life-saving for patients with advanced disease. Current medical therapy, which is directed toward the prevention of progression of the underlying liver disease, remains experimental and includes the use of antifibrogenic, immunosuppressive, and choleretic agents.
